Menu
×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Program Committee
-
Stephen Knowles, MD, MRCP • Chief Medical Officer
Halozyme Therapeutics, United States -
Lesley Wise, PhD, MSc • Managing Director
Wise PV&RM Ltd, United Kingdom -
Mariette Boerstoel-Streefland, MD, MBA, MS • Senior Vice President Patient Safety, Chief Safety Officer
AstraZeneca, United States -
Cheryl Campbell, MS • Associate Director of Executive Operations/Outreach and Communications, OSE,CDER
FDA, United States -
E. Stewart Geary, MD • Senior Vice President
Eisai Co., Ltd., Japan -
Lisa Melanie Harinstein, PharmD • Team Leader, Division of Pharmacovigilance, FDA
FDA, United States -
Jeremy Jokinen, PhD, MS • Vice President and Head, Global Risk Management & International Patient Safety
Bristol-Myers Squibb Company, United States -
Annette Stemhagen, DrPH, FISPE • Chief Scientific Officer
UBC, United States -
Sarah Vaughan • Head of Vigilance Development
Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom -
Annette S. Williams, MBA, RPh • Vice President, Pharmacovigilance
IQVIA, United States -
Jo Wyeth, PharmD • Associate Director for Postmarket Assessments, OMEPRM, OSE, CDER
FDA, United States -
Stella Blackburn, MD, MA, MSc, FFPM, FISPE, FRCP • Vice President, Strategic Operations
IQVIA, United Kingdom -
William Gregory, PhD • Senior Director, Safety and Risk Management
Pfizer Inc, United States -
Valerie E. Simmons, MD, FFPM • Senior Medical Fellow, Global Patient Safety
Eli Lilly and Company Ltd, United Kingdom
